BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ 2011;1:138-59. [PMID: 22034603 DOI: 10.4103/2045-8932.83444] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhao JH, He YY, Guo SS, Yan Y, Wang Z, Ye J, Zhang JL, Wang Y, Pang XB, Xie XM, Lin JH, Jing ZC, Han ZY. Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients. Am J Hypertens 2019;32:1109-17. [PMID: 31350549 DOI: 10.1093/ajh/hpz121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
2 Corboz MR, Li Z, Malinin V, Plaunt AJ, Konicek DM, Leifer FG, Chen K, Laurent CE, Yin H, Biernat MC, Salvail D, Zhuang J, Xu F, Curran A, Perkins WR, Chapman RW. Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug. J Pharmacol Exp Ther 2017;363:348-57. [DOI: 10.1124/jpet.117.242099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
3 Diaz-Rodriguez N, Nyhan SM, Kolb TM, Steppan J. How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00843-0. [PMID: 34649806 DOI: 10.1053/j.jvca.2021.09.030] [Reference Citation Analysis]
4 Luo F, Wu L, Xie G, Gao F, Zhang Z, Chen G, Liu Z, Zha L, Zhang G, Sun Y, Zhang Z, Wang Y. Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling. Hypertension 2021;77:1787-98. [PMID: 33775126 DOI: 10.1161/HYPERTENSIONAHA.120.15994] [Reference Citation Analysis]
5 Zimnicka AM, Tang H, Guo Q, Kuhr FK, Oh MJ, Wan J, Chen J, Smith KA, Fraidenburg DR, Choudhury MS, Levitan I, Machado RF, Kaplan JH, Yuan JX. Upregulated copper transporters in hypoxia-induced pulmonary hypertension. PLoS One 2014;9:e90544. [PMID: 24614111 DOI: 10.1371/journal.pone.0090544] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
6 Wei C, Kim IK, Li L, Wu L, Gupta S. Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. PLoS One 2014;9:e110598. [PMID: 25412097 DOI: 10.1371/journal.pone.0110598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
7 Carpio AM, Goertz A, Kelly C, Willes L, Quan SF, Pressman GS, Niroula A, Sharma S. Unrecognized pulmonary arterial hypertension in hospitalized patients. Int J Cardiovasc Imaging 2021;37:1237-43. [PMID: 33211240 DOI: 10.1007/s10554-020-02108-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wei C, Henderson H, Spradley C, Li L, Kim IK, Kumar S, Hong N, Arroliga AC, Gupta S. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One 2013;8:e64396. [PMID: 23717609 DOI: 10.1371/journal.pone.0064396] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
9 Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, Li Z, Perkins WR. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther 2020;65:102002. [PMID: 33596473 DOI: 10.1016/j.pupt.2021.102002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ballout FA, Manshad AS, Okwuosa TM. Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management. Curr Treat Options Cardiovasc Med 2017;19:44. [PMID: 28466120 DOI: 10.1007/s11936-017-0543-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Su H, Xu X, Yan C, Shi Y, Hu Y, Dong L, Ying S, Ying K, Zhang R. LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension. Respir Res 2018;19:254. [PMID: 30547791 DOI: 10.1186/s12931-018-0956-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
12 Wipprecht S, Wagner J, Bona A, Falvo L, Ahmed RA. Remodulin® Pump Failure: An Emergency Medicine Simulation Scenario. Cureus 2020;12:e8223. [PMID: 32582484 DOI: 10.7759/cureus.8223] [Reference Citation Analysis]
13 Chapman RW, Li Z, Corboz MR, Gauani H, Plaunt AJ, Konicek DM, Leifer FG, Laurent CE, Yin H, Salvail D, Dziak C, Perkins WR, Malinin V. Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. Pulmonary Pharmacology & Therapeutics 2018;49:104-11. [DOI: 10.1016/j.pupt.2018.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Rivera-Lebron BN, Risbano MG. Ambrisentan: a review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis 2017;11:233-44. [PMID: 28425346 DOI: 10.1177/1753465817696040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med 2020;21:163-79. [PMID: 32706206 DOI: 10.31083/j.rcm.2020.02.597] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
16 Kojonazarov B, Luitel H, Sydykov A, Dahal BK, Paul-Clark MJ, Bonvini S, Reed A, Schermuly RT, Mitchell JA. The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy. Pulm Circ 2013;3:926-35. [PMID: 25006409 DOI: 10.1086/674755] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
17 Shafiq M, Jagavelu K, Iqbal H, Yadav P, Chanda D, Verma NK, Ghosh JK, Gaestel M, Hanif K. Inhibition of Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2) is Protective in Pulmonary Hypertension. Hypertension 2021;77:1248-59. [PMID: 33641361 DOI: 10.1161/HYPERTENSIONAHA.120.15229] [Reference Citation Analysis]
18 Lopes AA. Is surgical treatment the cure for patients with congenital heart disease? Pulm Circ 2012;2:273-4. [PMID: 23130096 DOI: 10.4103/2045-8932.101391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
19 Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. Eur J Pharmacol 2021;:174484. [PMID: 34508752 DOI: 10.1016/j.ejphar.2021.174484] [Reference Citation Analysis]
20 Chen SH, Chen LK, Teng TH, Chou WH. Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis. Ann Med 2020;52:120-30. [PMID: 32204626 DOI: 10.1080/07853890.2020.1746826] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]